Black Swift Group LLC Acquires Shares of 7,700 Natera, Inc. (NASDAQ:NTRA)

Black Swift Group LLC purchased a new position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 7,700 shares of the medical research company's stock, valued at approximately $1,219,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in NTRA. Blue Trust Inc. raised its stake in shares of Natera by 104.3% during the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock worth $30,000 after purchasing an additional 97 shares in the last quarter. Versant Capital Management Inc grew its position in Natera by 345.8% in the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company's stock worth $34,000 after acquiring an additional 166 shares in the last quarter. Covestor Ltd raised its holdings in shares of Natera by 34.3% during the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company's stock valued at $47,000 after purchasing an additional 95 shares in the last quarter. Principal Securities Inc. boosted its holdings in Natera by 20.7% in the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock worth $54,000 after purchasing an additional 59 shares in the last quarter. Finally, True Wealth Design LLC bought a new position in Natera during the third quarter valued at about $57,000. 99.90% of the stock is owned by hedge funds and other institutional investors.

Natera Stock Performance

Natera stock traded down $8.03 on Monday, hitting $132.63. The company's stock had a trading volume of 2,613,012 shares, compared to its average volume of 1,334,642. Natera, Inc. has a one year low of $83.13 and a one year high of $183.00. The firm has a market cap of $17.93 billion, a P/E ratio of -75.36 and a beta of 1.80. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The company has a fifty day moving average price of $165.61 and a 200-day moving average price of $148.09.

Remove Ads

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.01. The firm had revenue of $476.10 million during the quarter, compared to analyst estimates of $447.91 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. On average, equities analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

Wall Street Analysts Forecast Growth

NTRA has been the topic of a number of recent analyst reports. Craig Hallum lifted their price target on shares of Natera from $121.00 to $157.00 and gave the company a "buy" rating in a research report on Wednesday, November 13th. Guggenheim lifted their target price on shares of Natera from $170.00 to $200.00 and gave the stock a "buy" rating in a report on Friday, January 17th. Piper Sandler raised their price target on Natera from $200.00 to $205.00 and gave the company an "overweight" rating in a research report on Tuesday, March 4th. JPMorgan Chase & Co. lifted their price objective on Natera from $160.00 to $200.00 and gave the stock an "overweight" rating in a research note on Friday, December 13th. Finally, Sanford C. Bernstein increased their target price on Natera from $160.00 to $200.00 and gave the company an "outperform" rating in a research note on Friday, January 10th. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $173.56.

Insider Activity at Natera

In other news, insider Solomon Moshkevich sold 6,000 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $143.29, for a total transaction of $859,740.00. Following the completion of the sale, the insider now owns 143,768 shares of the company's stock, valued at approximately $20,600,516.72. This trade represents a 4.01 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider John Fesko sold 669 shares of Natera stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $159.60, for a total transaction of $106,772.40. Following the completion of the transaction, the insider now owns 114,142 shares of the company's stock, valued at $18,217,063.20. This trade represents a 0.58 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 296,713 shares of company stock valued at $47,513,516 in the last 90 days. 7.60% of the stock is owned by corporate insiders.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.